Vicki Moore, PhD

Contributing Writer https://www.pulmonologyadvisor.com

Vicki Moore, PhD, is a freelance medical writer for Hematology Advisor. Vicki received her PhD in biology from Arizona State University, where her research emphasized molecular biology, biochemistry, and metabolic engineering. She also has experience with predictive analytics and is intrigued by its applications to medicine. Vicki has been a medical writer, focusing on areas of hematology and oncology, among other specialties, since late 2017. You can find her on Linkedin at linkedin.com/in/vicki-moore-93950913

All articles by Vicki Moore, PhD

An analysis showed that outcomes of SARS-CoV-2 infections can be disproportionately mild in some patient cohorts.

Lung Infection

Incidence of Asymptomatic SARS-CoV-2 Infection in Actively Treated Cancer

Vicki Moore, PhD

January 27, 2021

Researchers sought to determine the incidence of silent infection with SARS-CoV-2 among patients receiving cancer treatment in Italy during the peak of the pandemic.

General Pulmonology

Venous Thromboembolism Rates in Patients With SARS-CoV-2 Infection

Vicki Moore, PhD

November 24, 2020

In a new study, researchers reported on the frequency of VTE among more than 6000 patients who tested positive for infection with SARS-CoV-2.

Pulmonary Hypertension

Prevalence of Pulmonary Hypertension in Patients With Myeloproliferative Neoplasms

Vicki Moore, PhD

November 23, 2020

A new meta-analysis indicates that the true prevalence of pulmonary hypertension linked to myeloproliferative neoplasms is not well understood.

Anticoagulant efficacy to prevent VTE after hip and knee arthroplasty

Lung Infection

Venous Thromboembolism Events With COVID-19 in an Intensive Care Unit

Vicki Moore, PhD

August 6, 2020

COVID-19 ICU patients exhibited distinct phenotypic traits that suggested standard VTE prophylaxis is insufficient in this population.

Lung Cancer

Bodyweight-Based Dosing of Nivolumab Results in Wastage

Vicki Moore, PhD

June 29, 2020

A review of practices prior to a change in nivolumab dosing demonstrated that bodyweight dosing resulted in a 6.1% rate of wastage at a significant cost compared with a fixed dose of 240 mg per dose.

Lung Cancer

Prevalence and Experience With Cough in Patients With Lung Cancer

Vicki Moore, PhD

February 6, 2020

This cross-sectional study investigated the prevalence and severity of cough among patients with lung cancer who are undergoing treatment for their cancer, and compared these results with that of patients with lung cancer who are not undergoing treatment.

Next post in Lung Cancer

Vicki Moore, PhD

All articles by Vicki Moore, PhD

Incidence of Asymptomatic SARS-CoV-2 Infection in Actively Treated Cancer

Venous Thromboembolism Rates in Patients With SARS-CoV-2 Infection

Prevalence of Pulmonary Hypertension in Patients With Myeloproliferative Neoplasms

Venous Thromboembolism Events With COVID-19 in an Intensive Care Unit

Bodyweight-Based Dosing of Nivolumab Results in Wastage

Prevalence and Experience With Cough in Patients With Lung Cancer

Pulmonary Function Impairments May Increase Lung Cancer Susceptibility